Novavax Beheer

Beheer criteriumcontroles 1/4

Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $7.30M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth €407.85K. The average tenure of the management team and the board of directors is 1.8 years and 4.3 years respectively.

Belangrijke informatie

John Jacobs

Algemeen directeur

US$7.3m

Totale compensatie

Percentage CEO-salaris	9.1%
Dienstverband CEO	1.8yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is John Jacobs's beloning veranderd ten opzichte van Novavax's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$294m
Mar 31 2024	n/a	n/a	-US$399m
Dec 31 2023	US$7m	US$663k	-US$545m

Compensatie versus markt: John's total compensation ($USD7.30M) is above average for companies of similar size in the German market ($USD1.58M).

Compensatie versus inkomsten: Insufficient data to compare John's compensation with company performance.

CEO

John Jacobs (57 yo)

1.8yrs

Tenure

US$7,301,009

Compensatie

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Jacobs	President	1.8yrs	US$7.30m	0.030% € 407.8k
John Trizzino	President & COO	less than a year	US$1.88m	0.018% € 242.9k
James Kelly	Executive VP	3.3yrs	US$1.50m	0.0090% € 123.8k
Mark Casey	Executive VP	less than a year	US$1.53m	geen gegevens
Richard Crowley	Executive VP & COO	1.8yrs	geen gegevens	geen gegevens
Robert Walker	Senior VP	less than a year	geen gegevens	geen gegevens
Troy Morgan	Senior VP	no data	geen gegevens	geen gegevens
Erika Trahan	Associate Director of Investor & Public Relations	6.6yrs	geen gegevens	geen gegevens
Ian Watkins	Executive VP & Chief Human Resources Officer	1.3yrs	geen gegevens	geen gegevens
Silvia Taylor	Executive VP and Chief Corporate Affairs & Advocacy Officer	2.8yrs	geen gegevens	geen gegevens
Elaine O'Hara	Executive VP & Chief Strategy Officer	1.8yrs	geen gegevens	0.0089% € 122.1k

1.8yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: NVV1's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Jacobs	President	1.8yrs	US$7.30m	0.030% € 407.8k
David Mott	Independent Director	4.4yrs	US$187.53k	0.032% € 433.1k
Richard Douglas	Independent Director	14.8yrs	US$189.53k	0.027% € 376.8k
Margaret McGlynn	Independent Director	3.9yrs	US$185.02k	0.0065% € 89.8k
Gregg Alton	Independent Director	4.1yrs	US$175.28k	0.0065% € 89.8k
Rachel King	Independent Director	6yrs	US$174.55k	0.012% € 162.4k
Richard Rodgers	Independent Director	2.1yrs	US$191.78k	0.0065% € 89.8k
James Young	Independent Chairman of the Board	14.6yrs	US$222.53k	0.039% € 530.0k

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: NVV1's board of directors are considered experienced (4.3 years average tenure).

Novavax Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold €355k worth of stock

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Novavax, Inc. Announces Changes to Executive Leadership Team

High number of new directors

Novavax, Inc. Announces Chief Executive Officer Changes

Recent updates

Novavax, Inc Announces Update on Covid-19-Influenza Combination and Stand-Alone Influenza Phase 3 Trial

Forecast breakeven date pushed back to 2026

Novavax, Inc. Updated 2024-2025 Nuvaxovid™ Covid-19 Vaccine Receives Authorization in the EU

Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA

Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold €355k worth of stock

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Shareholder dilution

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Full year 2023 earnings released: US$5.41 loss per share (vs US$8.42 loss in FY 2022)

New minor risk - Profitability

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

New major risk - Shareholder dilution

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

New minor risk - Financial position

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

New minor risk - Profitability

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

No longer forecast to breakeven

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$6.53 loss in 2Q 2022)

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

New minor risk - Profitability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$3.41 loss per share (vs US$2.66 profit in 1Q 2022)

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2022 earnings released: US$8.42 loss per share (vs US$23.44 loss in FY 2021)

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021)

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults